COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

New European Guidelines on Pulmonary Embolism: What Has Changed and …

PERT Consortium 2021

S. Konstantinides

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

Acute DVT: When to and When Not to Intervene?

Venous Edge

S. Elias, C. Pena, C. Huff, R. Winokur, K. BROWN

TCT 2022: Why Intervene on Submassive Pulmonary Embolism Patients?

TCT 2022 Conference Coverage

W. Jaber

Extended Anticoagulation for VTE

Jeffrey Weitz

Medical Management of DVT

NY Endovascular Summit

J. Goldfinger

Catheter-Based Interventions for Acute Pulmonary Embolism: What Are …

Mount Sinai Endovascular Fellows Course

J. Giri

Update on HI-PEITHO - A Landmark Clinical Trial in PE

PERT Consortium 2022

K. Rosenfield

Pulmonary Embolism: Where Are We in 2024?

UPMC

B. Rivera-Lebron

Pulmonary Hypertension Due to Lung Disease / Chronic Pulmonary Embol…

Scripps Health

K. Fan

PE - The Great Masquerader: A Disease of Many Faces: Cases Where I W…

Pulmonary Embolism 2016

V. Tapson

Catheter-Directed Thrombolysis Is the Preferred Approach for the Tre…

PERT Consortium 2022

P. Monteleone

Regulatory Pathways for Devices for Management of Pulmonary Embolism…

PERT Consortium 2021

S. Lossef

Right Heart Failure Secondary to Non-Group 1 PH

Mayo Clinic Pulmonary and Critical Care Educational Series

H. Cajigas

Duration of Anticoagulation: Provoked vs Unprovoked VTE

PERT Consortium 2022

G. Barnes

Pulmonary Embolism: Risk Stratification and Management

Talal Dahhan

VTE Prevention in Medical Patients

PERT Consortium 2021

S. Schulman

Role of Thrombolysis for Patients With Acute Intermediate-Risk Pulmo…

CHEST 2022 Coverage

B. Dalal